Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

313291,196137,240Consolidated Balance Sheet DataAs of September 30,As of December 31,(In thousands)

20102009(unaudited)Cash and investments(1)

$  231,018$  162,513Obligations under line of credit

-(37,435)Cash and investments, net of obligations under line of credit(1)

231,018125,078Property and equipment, net

55,40458,754Goodwill

25,79825,798Other intangible assets

53,557-Total assets

370,873257,761Deferred revenue

15,05915,154Current and long-term debt, including line of credit

28,75466,964Noncontrolling interest in Symphony Icon, Inc.

-(290)Accumulated deficit

(650,407)(570,175)Total Lexicon Pharmaceuticals, Inc. stockholders' equity

268,854163,787——————(1)  Cash and investments at December 31, 2009 included $5.4 million held by Symphony Icon, Inc.  As a result of Lexicon's adoption as of January 1, 2010 of a   new accounting pronouncement regarding variable interest entities, the results of Symphony Icon were not consolidated in Lexicon's financial statements for the period from January 1, 2010 through the exercise of the purchase option on July 30, 2010.  
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") today ... research program with Emerald Logic, a leader ... Technology (FACET), Emerald Logic analyzed Resverlogix,s complete ... each of 798 patients who participated in ... SUSTAIN and ASSURE. The objective of this ...
(Date:3/4/2015)... Irvine, CA (PRWEB) March 04, 2015 ... research leader in Personalized Medicine, is excited to ... “Incorporating Genetic Testing to Optimize the Management of ... be available at Medscape.com for the next year. ... medical professionals how to recognize inadequate pain treatments, ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, ... and technology provider, today announced that clinical ... countries convened at its annual European User ... to discuss the use of its ... BioClinica,s eClinical technologies include: the Microsoft Office-Smart ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4
... and Harvard Deploys Isilon Clustered Storage to ... Growth, SEATTLE, Sept. 15 Isilon(R) Systems ... that the Broad,Institute of MIT and Harvard, one ... has deployed Isilon IQ clustered storage to,streamline mission-critical ...
... Inc.,(NYSE: BMR ) today announced that its board of ... share of common stock. The,dividend is equivalent to an annualized ... that its board of directors has declared a,dividend of $0.46094 ... Stock for the period from July 16, 2008 through,October 15, ...
... Sept. 12 Fougera, a division of Nycomed,US ... Clotrimazole Cream USP,1%. The generic formulation compares to ... three sizes: 15g tubes (NDC # 0168-0133-15), 30g ... 0168-0133-46)., "The approval of Clotrimazole Cream is ...
Cached Biology Technology:Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing 2Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing 3BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends 2
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... some other type of transcendent entity answer prayer? , ... study published in the March journal Research on Social ... of social work in the College of Human Services ... 17 major studies on the effects of intercessory prayer ...
... Worldwide, billions of people lack access to a reliable ... To address the problem, the United Nations established the ... of people without sustainable access to safe drinking water ... launched in 2000 as part of the U.N. Millennium ...
... When a virus infects a person, it triggers a series ... life or death consequences. , Usually, the result is ... virus and the infected person’s recovery. But in the case ... Marburg and Lassa fever viruses, as well as the influenza ...
Cached Biology News:Does God answer prayer? ASU research says 'yes' 2Failure to meet United Nations sanitation target could affect millions of the world's poorest 2Failure to meet United Nations sanitation target could affect millions of the world's poorest 3New study may show how to forestall a fatal, virus-caused immune-system meltdown 2New study may show how to forestall a fatal, virus-caused immune-system meltdown 3
...
Newborn Calf Serum US Origin...
SPDP-Trinitrophenol (TNP) Bovine Serum Albumin...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Biology Products: